Jason Haas - 12 Oct 2021 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Financial Officer
Signature
/s/ Jason Haas
Issuer symbol
SYRS
Transactions as of
12 Oct 2021
Net transactions value
$0
Form type
4
Filing time
13 Oct 2021, 16:06:51 UTC
Next filing
17 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +750,000 $0.000000 750,000 12 Oct 2021 Common Stock 750,000 $4.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one quarter (1/4th) of the shares on October 12, 2022, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.